Table 1:

Baseline characteristics

BevacizumabAll (N = 202)
No (N = 61)Up-Front (N = 69)Recurrence (N = 72)
Age (yr) (mean)55.7 ± 13.056.8 ± 9.256.0 ± 12.656.2 ± 11.6
Age range (yr)23–7931–7225–7723–79
Male (%)40 (66%)38 (55%)36 (50%)114 (56%)
Median survival (days ± IQR)a628 (±c588 (± 356) 752 (± 1023) 553 (± 507)
Gross total resection (yes/no) (% in yes)a28/33 (46%)27/42 (39%) 41/31 (57%)96/106 (48%)
Methylation (M1/U2/X3)b24/36/124/45/026/35/1174/116/12
IDH1 mutant/wild type7/544/653/6914/188
nCET (yes/no) (% in yes)20/41 (32%)22/47 (35%) 21/51 (33%)63/139 (32%)
Edema (no, mild/moderate, severe) (% in no or mild)28/33 (46%)22/47 (32%) 23/49 (32%)73/129 (36%)

  • Note:—M indicates methylated; U, unmethylated;. X, unknown.

  • ↵a P = .10 among 3 bevacizumab groups.

  • ↵b P = .65 for the only-methylated-versus-unmethylated group.

  • ↵c Undefined 75% due to censoring; 25% survival was 293 days.